This activity was originally presented at the 2024 HOPA Annual Conference in Tampa, Florida.
Program Description
With the emergence of Janus associated kinase (JAK) inhibitors as pivotal agents in managing myelofibrosis (MF), the role of oncology pharmacists has become increasingly vital in ensuring optimal patient outcomes. The selection and sequencing of JAK inhibitor therapies in MF are influenced by disease characteristics, patient comorbidities, and treatment response. Oncology pharmacists must stay abreast of emerging data for the JAK inhibitors, updates to treatment guidelines, and ongoing clinical trials to facilitate informed treatment decisions, especially in patients who are intolerant to or refractory to first-line JAK inhibitor therapy or who present with MF-associated anemia. This activity will examine strategies for evidence-based treatment sequencing in MF and equip pharmacists to optimize therapy while minimizing treatment-related adverse effects. Additionally, oncology pharmacists will develop strategies for proactive monitoring and management of common and rare adverse effects associated with JAK inhibitors.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: April 12, 2024
Expiration date: April 12, 2025
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Ensure appropriate treatment selection for individual patients with myelofibrosis (MF) considering patient- and disease-specific factors
- Identify signs and symptoms of disease progression in patients with MF and strategies for safe transition to subsequent treatment
- Implement evidence-based interventions to address symptoms of MF and associated treatments such as anemia and infection risk
Shawn Griffin, PharmD, BCOP
Assistant Clinical Professor
University of California Irvine School of Pharmacy & Pharmaceutical Sciences
Irvine, California
Kristen McCullough, PharmD, MS, BCPS, BCOP
Hematology Clinical Pharmacy Specialist
Mayo Clinic
Assistant Professor of Medicine & Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota
Amber B. Clemmons, PharmD, BCOP, FHOPA
Clinical Professor
The University of Georgia College of Pharmacy
Clinical Pharmacy Specialist, Hematology/BMT
Wellstar-MCG Health
Augusta, Georgia
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-100-H01-P. The activity is available for CE credit through April 12, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Amber B. Clemmons, PharmD, BCOP, FHOPA, Shawn Griffin, PharmD, BCOP, and Kristen McCullough, PharmD, MS, BCPS, BCOP, have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Abigail Dill; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no financial relationships with commercial interests to disclose.
Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here